Cite
HARVARD Citation
Carlucci, P. et al. (n.d.). 1702 Patients enrolled in the accelerating medicines partnership (AMP) RA/SLE network with isolated renal disease report minimal quality of life impairment on PROMIS-29 compared to patients with extrarenal symptoms. Lupus science & medicine. pp. A102-A103. [Online].